Pharmaceutical

Anticipation rises for RSV rollout as positive data emerges

Following major successes in the RSV landscape over the last few years, experts debate rollout plans.

Feb 24, 2024 - 18:00
Following major successes in the RSV landscape over the last few years, experts debate rollout plans.
Read the original article

Tags:

Previous Article

FDA to decide on Sanofi/Regeneron’s Dupixent for COPD in June

Next Article

Bavarian Nordic’s chikungunya vaccine secures EMA fast-track

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Democrats already want to expand Medicare drug price negotiation

STAT+: Democrats already want to expand Medicare drug p...

Jul 26, 2023

STAT+: Backed by Mayo Clinic and Microsoft, a nonprofit forms to test AI tools used in health care

STAT+: Backed by Mayo Clinic and Microsoft, a nonprofit...

Jan 8, 2024

Opinion: Medicaid adult dental benefits are shamefully — and dangerously — inadequate in most states

Opinion: Medicaid adult dental benefits are shamefully ...

Jun 14, 2023